Antiviral drug resistance: clinical consequences and molecular aspects.
about
KASL clinical practice guidelines: management of chronic hepatitis BOverview of hepatitis B virus mutations and their implications in the management of infectionLiver transplantation for viral hepatitis in 2015Prophylaxis against Recurrence in Liver Transplantation Patients with Hepatitis B Virus: What is New?Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.Clinical implications of hepatitis B virus mutations: recent advances.Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy.A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B.Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategiesTenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.Clinical relevance of hepatitis B virus variantsMultidrug-resistant hepatitis B virus strain in a chronic Turkish patient.Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapiesKASL Clinical Practice Guidelines: Management of chronic hepatitis B.Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected populationDrug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B.A case report of de novo hepatocellular carcinoma after living donor liver transplantationResistance issues in treating chronic hepatitis B.Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.Monotherapy versus combination therapy for the treatment of chronic hepatitis B.Management of Antiviral Resistance in Chronic Hepatitis B.A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.Antiviral drugs for HBV liver disease.Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation.Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristicsCombined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).Chronologic changes in serum hepatitis B virus DNA, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan.Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.Viral resistance in hepatitis B: prevalence and management.Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation.Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis BIntracellular levels of hepatitis B virus DNA and mutational patterns of the polymerase gene of hepatitis B virus in peripheral blood mononuclear cells of patients with lamivudine or telbivudine resistance.Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report.Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.Hepatitis B virus reverse transcriptase mutations in treatment Naïve chronic hepatitis B patients.An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcriptionDetection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran.The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir.
P2860
Q26752475-19512174-DEDD-4294-954B-324F100EBAE4Q26772346-E2D57725-4C02-4216-A98D-B22A61BE02D2Q26773224-BC402AEC-55BA-41D4-9D7C-E79C03DBF46BQ26781880-E9D206FF-07A0-4C16-8468-703FA013C893Q33492413-DEA05363-B73B-4B86-94AB-995BF50117F3Q33801311-FE288689-8BA4-40CD-B563-47A144882DF5Q34303163-05C5759C-6B54-4232-84BB-6C3E0FEAFBE7Q35507167-98A3A617-8117-490F-8A95-7E27E7311ADAQ35603841-886C251E-F7AD-42BF-9E4B-D62E72FA07B0Q35639847-F8FA1B2C-B84C-4FBC-8E0B-3C985E9E64EAQ35668730-8B667912-DCF2-4522-B50C-E85B6E93E968Q35724618-77FDA7A9-6A0B-4A9A-B787-1626A49B3BB5Q36145282-77276A78-C110-4C03-8688-E018DF1F6010Q36153966-9AEBC9AD-FD82-419E-8F76-C3D80FA6D0D9Q36752382-3F3D3149-80E9-4E24-AC60-05EBBE8E4F7AQ36765571-5955F4A9-5796-4DFE-A33B-5825E2965A4BQ36903952-841A703C-072F-4249-B084-C67D119CD202Q37116722-C977FED8-9530-4618-8E76-D21A6AC0169CQ37277073-CB7CD01E-0402-4306-ADE1-7FADD72C8FFBQ37393925-AED03ADC-B6D2-442D-B8F5-08FB228D98A1Q37620354-23D5425C-6ED7-4F08-8485-0133BA732E35Q37696029-6CDF6390-0F7C-4024-889E-64C1CD8565C8Q37768591-41F46A87-8C11-4ADC-AD5E-146F278AF803Q37825909-A6FB6AC0-1E75-4BC9-BF8D-A1D44E890F5AQ38071401-D60C05ED-1332-488C-9700-150C82E49917Q38177252-2E10A4F4-8415-4EAF-9557-49F74B45D9E8Q38408911-53B0344F-86AD-402C-BBB5-EC40DDCC3CB2Q38424625-C9BEEEB0-F872-4DD6-A0B6-7F58D5797C73Q38969885-3D529B76-B347-4928-9372-57D41C205B7EQ39277056-25446CE1-C698-4F96-986A-993839FE2F59Q39429039-144F5896-B143-4131-977D-6DCACDDC010BQ39716344-172A66E8-8F9B-4877-ABAF-9233236343E1Q40957068-598F3164-04E2-4163-B7DE-F717088A603DQ41492511-BBA9E77C-95F5-40EE-B6FF-9086B8D5CB5EQ41965007-1C186B88-DA3F-42D2-8EC1-1D8E9F906E06Q42270061-C0339AF5-6DF7-4106-9395-7C2F157BE5EEQ42278809-84F23269-82C8-44DB-8F84-E84E0D637F30Q42545491-AB5206EE-D4F6-48BB-801B-60E3403BD07AQ43243611-79A8D66B-57D4-4990-80E3-67FBB0E49716Q43824738-07487413-230D-4434-AA9A-036B7FFC9C2C
P2860
Antiviral drug resistance: clinical consequences and molecular aspects.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antiviral drug resistance: clinical consequences and molecular aspects.
@ast
Antiviral drug resistance: clinical consequences and molecular aspects.
@en
type
label
Antiviral drug resistance: clinical consequences and molecular aspects.
@ast
Antiviral drug resistance: clinical consequences and molecular aspects.
@en
prefLabel
Antiviral drug resistance: clinical consequences and molecular aspects.
@ast
Antiviral drug resistance: clinical consequences and molecular aspects.
@en
P356
P1476
Antiviral drug resistance: clinical consequences and molecular aspects.
@en
P2093
Angeline Bartholomeusz
Stephen A Locarnini
P304
P356
10.1055/S-2006-939758
P577
2006-05-01T00:00:00Z